Rosiglitazone formulations
Rosiglitazone is a drug used to treat type 2 diabetes. Methods for the formation of amorphous rosiglitazone and formulations comprising the amorphous rosiglitazone are described. Other formulations include pulsed-release formulations and formulations for retention in the stomach and upper gastrointestinal tract. Controlled-release dosage form include those wherein the maximum plasma concentration of rosiglitazone occurs greater than one hour after administration to a human and/or wherein less than 75 percent by weight of the rosiglitazone is released at 1 hour after immersion in simulated gastric fluid.
1 . A dosage formulation, comprising:
an active agent, wherein the active agent is amorphous rosiglitazone or an amorphous pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable polymeric carrier, wherein the polymeric carrier maintains the active agent in substantially amorphous form.
2 . The dosage formulation of claim 1 , wherein the polymeric carrier is an ion-exchange resin, a reducing solvent, a hydroxypropyl cellulose, a methyl cellulose, a carboxymethyl cellulose, a sodium carboxymethyl cellulose, a cellulose acetate phthalate, a cellulose acetate butyrate, a hydroxyethyl cellulose, a ethyl cellulose, a polyvinyl alcohol, a polypropylene, a dextran, a dextrin, hydroxypropyl-beta-cyclodextrin, chitosan, a co(lactic/glycolid) copolymer, a poly(orthoester), a poly(anhydrate), a polyvinyl chloride, a polyvinyl acetate, an ethylene vinyl acetate, a lectin, a carbopol, a silicon elastomer, a polyacrylic polymer, a maltodextrin, polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone, a polyethylene glycol, an alpha-cyclodextrins, a beta-cyclodextrin, a gamma-cyclodextrin, or a combination comprising one or more of the foregoing polymeric carriers.
3 . (canceled)
4 . The dosage formulation of claim 1 , wherein the active agent is rosiglitazone maleate.
5 . (canceled)
6 . The dosage formulation of claim 1 , further comprising an excipient, wherein the excipient is a diluent, a binder, a disintegrant, a coloring agent, a flavoring agent, a lubricant, a preservative, or a combination comprising one or more of the foregoing excipients.
7 . The dosage formulation of claim 1 , wherein the formulation is in the form of a tablet, a capsule, a soft-gel, or a powder.
8 . The dosage formulation of claim 1 , wherein the formulation provides an AUC between 0 and 24 hours after administration that is more than 80 percent and less than 120 percent of the AUC provided by an equivalent weight of AVANDIA® between 0 and 24 hours after administration.
9 - 19 . (canceled)
20 . A controlled-release oral dosage form comprising rosiglitazone or a pharmaceutically acceptable salt thereof dispersed in a solid polymeric matrix, wherein the solid polymeric matrix swells upon imbition of water, wherein the solid polymeric matrix retains greater than or equal to about 40 weight percent of the rosiglitazone one hour after immersion in simulated gastric fluid, and wherein the solid polymeric matrix remains substantially intact until substantially all of the rosiglitazone or pharmaceutically acceptable salt thereof is released.
21 . The dosage form of claim 20 , wherein the solid polymeric matrix releases substantially all of the rosiglitazone or pharmaceutically acceptable salt thereof within eight hours of immersion in simulated gastric fluid.
22 . The dosage form of claim 20 , wherein the rosiglitazone or pharmaceutically acceptable salt thereof is in amorphous form.
23 . The dosage form of claim 20 , wherein the pharmaceutically acceptable salt of rosiglitazone is rosiglitazone maleate.
24 . The dosage form of claim 20 , wherein the ratio of the rosiglitazone or pharmaceutically acceptable salt thereof to the polymeric matrix is about 15:85 to about 80:20.
25 . The dosage form of claim 20 , wherein the polymeric matrix is a cellulose, an alkyl-substituted cellulose; a poly(alkylene oxide), a polysaccharide gum, a polyacrylic acid, or a combination comprising one or more of the foregoing matrices.
26 - 30 . (canceled)
31 . The dosage form of claim 20 , wherein the solid polymeric matrix retains greater than or equal to about 60 weight percent of the rosiglitazone or pharmaceutically acceptable salt thereof after one hour of immersion in simulated gastric fluid.
32 . The dosage form of claim 20 , wherein the solid polymeric matrix retains greater than or equal to about 80 weight percent of the rosiglitazone or pharmaceutically acceptable salt thereof after one hour of immersion in simulated gastric fluid.
33 . The dosage form of claim 20 , further comprising a hydrophobic additive to further retard the release of the rosiglitazone or pharmaceutically acceptable salt thereof.
34 - 49 . (canceled)
50 . A controlled-release dosage form comprising rosiglitazone or a pharmaceutically acceptable salt thereof, wherein a peak plasma concentration occurs greater than 1 hour after administration to a human in the absence of food.
51 . The controlled-release dosage form of claim 50 , wherein the peak plasma concentration occurs greater than 2 hours after administration to a human in the absence of food.
52 . The controlled-release dosage form of claim 50 , wherein the peak plasma concentration occurs greater than 4 hours after administration to a human in the absence of food.
53 . The controlled-release dosage form of claim 50 , wherein the pharmaceutically acceptable salt of rosiglitazone is rosiglitazone maleate.
54 . The controlled-release dosage form of claim 50 , wherein the rosiglitazone or pharmaceutically acceptable salt thereof is in amorphous form.
55 - 62 . (canceled)